Serum Syndecan-1 Levels and Its Relationship to Disease Activity in Patients with Crohn’s Disease

• Main Authors: Cem Çekiç, Adnan Kırcı, Sezgin Vatansever, Fatih Aslan, Huriye Erbak Yılmaz, Emrah Alper, Mahmut Arabul, Elif Sarıtaş Yüksel, Belkıs Ünsal
• Format: Article
• Language: English
• Published: Hindawi Limited 2015-01-01
• Series: Gastroenterology Research and Practice
• Online Access: http://dx.doi.org/10.1155/2015/850351
• ISSN: 1687-6121; 1687-630X

Background. Syndecan-1 (SDC-1), a member of the family of heparan sulfate proteoglycans, plays an important role in the resolution of inflammation. This study aimed to investigate the relationship between SDC-1 and disease activity in Crohn’s disease (CD). Methods. Serum samples of 54 patients with CD and 30 healthy controls were obtained. First, SDC-1 levels of the CD patients were compared to the control group. Subsequently, SDC-1 levels were analyzed in patients with CD in active and remission periods. Finally, SDC-1 efficacy in predicting disease activity was evaluated by performing correlation analysis between SDC-1 and C-reactive protein (CRP) and Crohn’s disease activity index (CDAI). Results. SDC-1 level was higher in the CD group (61.9 ± 42.6 ng/mL) compared with the control group (34.1 ± 8.0 ng/mL) p=0.03. SDC-1 levels were higher in active CD patients (97.1 ± 40.3 ng/mL) compared with those in remission (33.7 ± 13.5 ng/mL) p<0.001. A significant positive correlation was found between SDC-1 and CRP (r=0.687, p<0.001) and between SDC-1 and CDAI (r=0.747, p<0.001). Conclusion. Serum levels of SDC-1 are higher in CD compared to the normal population and can be an effective marker of disease severity.